Global InformationIstiratumab information
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | IGF1R, ErbB3 |
| Clinical data | |
| Other names | MM-141 |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C8802H13532N2392O2796S58 |
| Molar mass | 199458.51 g·mol−1 |
Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.[1]
It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.[2]
- ^ Alternative Names: MM-141. "Istiratumab - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL : USAN (CD-106) ISTIRATUMAB" (PDF). Searchusan.ama-assn.org. Retrieved 2017-05-23.